Case Report and Literature Review: Endometrial Carcinoma in a Postmenopausal Patient Treated with Tamoxifen for Breast Cancer

Kamal Hamed, Sarah Mirghani


Tamoxifen is a selective estrogen receptor modulator. It is commonly used in the treatment of patients with hormone receptor positive breast cancer.The early breast cancer trialist group ,EBCTCG meta-analysis reported that 5 years of adjuvant Tamoxifen treatment resulted in reduction in recurrence and mortality by 47% and 26% respectively, and reduced the incidence of contralateral breast cancer by 47% (1). Tamoxifen is also used for chemoprevention in women at high risk for developing breast cancer,and those with 5-year breast cancer risk > 1.7%.  The benefit was found to be 49% in women > 35 years old(2). A number of studies have confirmed the relation between Tamoxifen and development of endometrial cancer that has a very low, yet a serious incidence. The cumulative risk of endometrial cancer with Tamoxifen use is 1.6% at five years and 3.1% if used for 5-10 yrs(3).Tamoxifen has  antagonistic and  agonistic effects. When it exerts its agonistic effect on the endometrium in postmenopausal women it may lead to a number of effects ranging from hyperplasia to endometrial cancer(3).


Case Report ;Literature Review;Endometrial Carcinoma; Postmenopausal Patient Treated ; Tamoxifen ;Breast Cancer

Full Text:



Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351:1451-67. 2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88.

Kamal Hamed, Sarah Mirghani

Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527-37. 4. Susan J Freeman,Ahmed M Aly,Masaka Y, Helen C. Addley, Caroline Reinhold, Evis Sala .The Revised FIGO Staging System for Uterine Malignancies: Implications for MR Imaging .Radiographics.2012;32: 1905—1827. 5. Yongfeng Shang .Genomic action of estrogens and tamoxifen in the uterus, from the article: Molecular mechanisms of estrogens and SERMs in endometrial carcinogenesis .Nature Reviews Cancer.2006 ;6:361 6. Berliere M, Radikov G, Galant C, Piette P, Marbaix E, Donnez J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer. 2000;36,Suppl 4:S35-6. 7. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer, J Natl Cancer Inst. 2004; 96:7074. 8. Fornander T, Rutqvist LE, Cedermark B,et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers.The Lancet,1989;1:117—120 9. Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop CaEndometrium. J Obs and Gynae .2004;104,:255--260 10. Barakat RR, Gelwski TA ,Almadrones L,et al.Effects of adjuvant tamoxifen in women with breast cancer in endometrial biopsies . J Clin Oncol. .2000 18:3459—3463.

Jones ME, van Leeuwen FE, Hoogendoorn WE,et al .Endometrial cancer survival after

breast cancer in relation to tamoxifen treatment ,pooled results from three countries. Breast Cancer Research.2012;14 R91. 12. Rutqvist LE1, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies Stockholm Breast Cancer Study Group. J Natl Cancer Inst.1995;87:645-651.


  • There are currently no refbacks.

ISSN: 1858-5345